Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1819790 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $59.54Day +1.74%Mkt cap $2.5B1Y +48.8%Off 52W high −30.2%Vol (1Y) 46.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.4% of sh out |
| Days to cover3.2d |
| 13F net flow (QoQ)+0.93% |
| Top-10 13F concentration51.4% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$535.1M |
| Earnings (TTM)-$48.3M |
| ROE−23.4% |
| Net margin−14.7% |
| ROIC−25.8% |
| Debt / equity0.21× |
| Sales growth 3Y159.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−27.3% |
| 1Y+48.8% |
| 3Y+170.5% |
| 5Y+163.8% |
| Since incept. (ann.)+10.6% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)46.6% |
| Ann. volatility (3Y)54.6% |
| Sharpe (1Y)1.09 |
| Sharpe (3Y)0.89 |
| Max drawdown (1Y)−32.0% |
| Max drawdown (3Y)−45.1% |
| Beta (3Y vs SPY)0.51 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.6M | $253M | 8.46% | +19.8% |
| BlackRock, Inc. | 3.6M | $249M | 8.35% | −6.3% |
| RTW INVESTMENTS, LP | 3.3M | $235M | 7.86% | +0.3% |
| Paradigm Biocapital Advisors LP | 2.6M | $180M | 6.02% | +0.0% |
| JANUS HENDERSON GROUP PLC | 2.2M | $157M | 5.27% | +16.1% |
| MORGAN STANLEY | 1.9M | $136M | 4.57% | −4.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.8M | $124M | 4.14% | new |
| JENNISON ASSOCIATES LLC | 1.7M | $120M | 4.02% | −23.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 106.1% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 4,817,273 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.16 | — | $162.1M | +106.9% |
| 2025-12-31 | 2026-02-23 | — | — | $151.7M | +128.4% |
| 2025-09-30 | 2025-11-04 | −$0.30 | — | $118.7M | +146.7% |
| 2025-06-30 | 2025-08-06 | −$0.48 | — | $102.7M | +151.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
